Physician profile
Mark Garcia
NPI 1861847048
$3,216.83
in general payments reported to CMS, 2019-2025
13 companies · $653 in 2025
The $653 reported for 2025 was more than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $258 · 2022: $571 · 2023: $375 · 2024: $1,359 · 2025: $653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,217 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,217.42 |
| Education | $169.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $1,569.92 | 2021-2025 | Rylaze, Defitelio |
| Genetix Biotherapeutics INC | $436.82 | 2024-2025 | Lyfgenia |
| Sobi, INC | $350.22 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $219.49 | 2024 | |
| Sanofi-Aventis U.S. LLC | $202.72 | 2024 | |
| Incyte Corporation | $152.46 | 2022-2025 | Niktimvo |
| Uswm, LLC | $97.08 | 2025 | Iwilfin |
| Fennec Pharmaceuticals, INC. | $72.28 | 2024 | Pedmark |
| Adaptive Biotechnologies Corporation | $25.70 | 2024 | Clonoseq |
| Alexion Pharmaceuticals, INC. | $23.96 | 2024 | Ultomiris |
| Mesoblast, INC. | $23.86 | 2025 | Ryoncil |
| Pharming Healthcare, INC. | $21.76 | 2025 | |
| Syndax Pharmaceuticals, INC. | $20.56 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Garcia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.